Tilray Cannabis Sales Fall 5% Sequentially in Q1

Tilray Brands reported robust first-quarter fiscal 2026 results, achieving record net revenue of $210 million and a net income of $1.5 million, a significant turnaround from a prior-year loss. The company also saw a 9% increase in Adjusted EBITDA to $10.2 million and a substantial $34 million improvement in cash used in operations, alongside a strengthened balance sheet with $265 million in cash and reduced net debt. These operational efficiencies and segment growth, particularly in Canadian and international cannabis, position Tilray to capitalize on evolving market opportunities, as it reiterates its fiscal year 2026 Adjusted EBITDA outlook of $62 million to $72 million.

Analysis

Tilray Brands (TLRY) reported a strong Q1 Fiscal 2026, achieving record net revenue of $210 million, a 5% year-over-year increase. Notably, the company swung to a net income of $1.5 million from a net loss of $(34.7) million in the prior year, demonstrating significant operational improvement. Adjusted EBITDA also grew 9% to $10.2 million, reinforcing profitability trends.

Operational efficiencies are evident in the $34 million improvement in cash used in operations, reducing it to $(1.3) million. The balance sheet strengthened significantly, with $265 million in cash and net debt reduced to $4 million, resulting in a low net debt to trailing twelve months adjusted EBITDA ratio of 0.07x. This provides substantial financial flexibility for strategic initiatives.

The company maintained its #1 position in Canadian adult-use cannabis, with gross revenue increasing 12% and expanding market share, alongside 10% growth in international cannabis revenue. While overall gross margin slightly declined to 27% from 30%, the reiterated Fiscal Year 2026 Adjusted EBITDA outlook of $62 million – $72 million signals management's confidence in continued profitability and market leadership, particularly with potential US cannabis rescheduling.

Key Decisions for Investors

• Investors should note the significant financial turnaround, evidenced by the shift to net income and improved operational cash flow, alongside a strengthened balance sheet with substantial cash reserves and minimal net debt.
• Monitor Tilray's continued market share expansion in Canadian and international cannabis, as well as progress on US cannabis rescheduling, which could serve as a significant catalyst for future growth.
• While gross margins across several segments experienced slight compression, the reiterated FY26 Adjusted EBITDA guidance suggests management's confidence in maintaining profitability, warranting a closer look at cost management strategies.